Navigation Links
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Date:1/4/2008

- Studies to investigate safety and efficacy in treatment of multi-drug

resistant infections -

NEW HAVEN, Conn., Jan. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a biopharmaceutical company focused on the development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the enrolment of the first patients in two separate Phase 2 clinical trials. The studies will evaluate the safety and efficacy of RX-1741 in the treatment of Community-Acquired Pneumonia (CAP), and separately in the outpatient treatment of Uncomplicated Skin and Skin Structure Infections (uSSSI). RX-1741 is the Company's first antibiotic program developed using its proprietary technology platform.

RX-1741 is an oxazolidinone antibiotic that exhibits activity against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, and has demonstrated both greater spectrum and potency of activity than the currently marketed product of the same class, Zyvox(R) (linezolid). Discovered using proprietary knowledge of the three dimensional structure of a key area of the ribosome, the 50S subunit, Rib-X believes that RX-1741 will demonstrate a high level of effectiveness against resistant microbes.

"These two studies represent important milestones for Rib-X," said Dr. Susan Froshauer, President and CEO of Rib-X Pharmaceuticals. "RX-1741 is the first of many compounds that Rib-X intends to design and develop in response to the alarming growth of drug resistant microbial pathogens found both in the hospital and in the community. This MRSA-active agent will satisfy a critical need for physicians and their patients because current treatment options are very limited, particularly for orally active agents," said Dr. Froshauer.

CAP Study Design

The CAP study is a Phase 2, multicenter, randomized, double-blind study designed to evaluate the safety and efficacy
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
2. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
9. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... 10, 2011 Boston Scientific Corporation (NYSE: ... a clinical education program and online resource center for ... spinal cord stimulation (SCS) technology, procedures and techniques.  The ... the International Spine Intervention Society (ISIS) occurring this week ...
... Verenium Corporation (Nasdaq: VRNM ), a leading industrial ... enzymes, today reported a summary of recent Company highlights and ... June 30, 2011. "I am very pleased with ... partnership negotiations in the first half of the year," said ...
... NEW YORK, Aug. 9, 2011 Reportlinker.com ... is available in its catalogue: ...     http://www.reportlinker.com/p0591346/ ... Biochips, DNA Chips, Genosensors, Microarrays and Labs-on-the-Chip ...
Cached Biology Technology:Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 3Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9Biochips: Genosensors, Microarrays, Labs-On-The-Chip 2
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... when a mouse repeatedly experiences defeat by a dominant ... memory molecule in a brain circuit for social learning, ... National Institute of Mental Health (NIMH) have discovered. ... welcome strangers in spite of repeated social defeat. Their ...
... cure rate for the once almost universally fatal childhood ... in the near future, thanks to improvements in diagnosis ... investigators at St. Jude Children's Research Hospital. Almost 4,000 ... each year, about two-thirds of which are in children ...
... in repairing damaged DNA causes mice to develop the ... have discovered. , Scientists at OHSU, the University of ... that generating mice that lack the gene encoding the ... obesity and reach nearly twice the weight of their ...
Cached Biology News:Mice lacking social memory molecule take bullying in stride 2Mice lacking social memory molecule take bullying in stride 3St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Removing DNA repair gene causes metabolic syndrome 2Removing DNA repair gene causes metabolic syndrome 3
... The FDSS6000 System is an ... assays, assay development and high throughput ... and luminescence modalities., The Hamamatsu light ... highlight our companys decades-long experience in ...
...
... supplies, for 10 chips, provides the ... high-sensitivity RNA analysis (picogram levels) with ... electrophoresis system. Supplied are 1,250 microliters ... stain, 20 microliters RNA ladder, 900 ...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. ... GAS. A cell-permeable sulfanamido-benzbromarone compound that ... non-competitive allosteric inhibitor of PTP1B (IC ... 8 μM for PTP1B 403 ...
Biology Products: